Royalty Pharma plc (RPRX) Operating income 2018–2025
Royalty Pharma plc (RPRX) annual operating income history from SEC filings — each fiscal year as reported.
$1.6BFY2025 · since FY2018: $1.4B → $1.6B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $1.6B | +20.7% |
| FY2024 | $1.3B | -13.4% |
| FY2023 | $1.5B | +385.9% |
| FY2022 | $307.1M | -78.5% |
| FY2021 | $1.4B | -10.3% |
| FY2020 | $1.6B | -39.2% |
| FY2019 | $2.6B | +92.3% |
| FY2018 | $1.4B | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More RPRX financial trends
RPRX RevenueRPRX Net incomeRPRX Net marginRPRX Gross profitRPRX Gross marginRPRX Operating marginRPRX Operating cash flowRPRX Free cash flowRPRX Capital expendituresRPRX Return on equityRPRX Stock buybacksRPRX Dividends paidRPRX Total assetsRPRX Total liabilitiesRPRX Shareholders’ equityRPRX overview →